Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14746156 | 0.99 | MCHR1 (0.37) | MCHR1FAAHTLR9TLR7TLR8 | |
| SCHEMBL14741232 | 0.98 | MCHR1 (0.36) | MCHR1FAAHTLR9TLR7TLR8 | |
| SCHEMBL14744911 | 0.94 | FAAH (0.35) | MCHR1FAAHTLR9TLR7TLR8 | |
| SCHEMBL14745070 | 0.94 | FAAH (0.38) | MCHR1FAAHTLR9TLR7TLR8 | |
| SCHEMBL14757643 | 0.93 | MCHR1 (0.34) | MCHR1FAAHTLR9TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL14745257 | 0.93 | FAAH (0.35) | MCHR1FAAHTLR9TLR7TLR8 | |
| SCHEMBL14745492 | 0.93 | FAAH (0.35) | MCHR1FAAHGAA | |
| Hydrochloric Acid SCHEMBL17597442 | 0.93 | FAAH (0.37) | MCHR1FAAHTLR9TLR7TLR8 | |
| SCHEMBL14745440 | 0.93 | MCHR1 (0.39) | MCHR1FAAHTLR9TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL14740922 | 0.93 | MCHR1 (0.33) | MCHR1FAAHTLR9TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | claimed |
| WO-2016039937-A1 | BICYCLIC AND TRICYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | claimed |
| EP-2750504-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| CN-103889224-A | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS INC | 2014-06-25 | — | — | CN | claimed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2016039937-A1 | BICYCLIC AND TRICYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2750504-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| CN-103889224-A | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS INC | 2014-06-25 | — | — | CN | disclosed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | MCHR1 4817/4885FAAH 4028/4885TLR9 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.